Anti-Mouse CD155 (PVR) [Clone 4.24.1] — Purified in vivo PLATINUM™ Functional Grade

Clone 4.24.1 is a monoclonal antibody targeting mouse CD155 (PVR), and it is used in in vivo mouse studies primarily to block or detect CD155 function. In these studies, clone 4.24.1 enables researchers to investigate the biological role of CD155, especially in immunological and cancer-related models.

Key applications and use:

• In vivo blocking/neutralization: Clone 4.24.1 is administered to mice to block CD155 activity, allowing analysis of how CD155 influences immune responses, tumor growth, or metastatic spread.
• Functional assays: After administration, its effects on T cell activation, cytokine production, or tumor progression can be measured, often by monitoring tumor size, metastasis rates, or immune cell activity in treated versus control animals.
• Mouse Strains: Studies have used clone 4.24.1 in multiple mouse strains (e.g., C57BL/6, BALB/c, genetically modified mice deficient in CD155), enabling comparison of immune responses in normal versus CD155-deficient contexts.

Experimental context:

• Dose and route: The antibody is typically injected intravenously, intraperitoneally, or subcutaneously, depending on the experimental design.
• Measurement of outcomes: Effects are evaluated via flow cytometry, imaging (e.g., IVIS for tumor/organ imaging), ELISA, or functional cell assays such as IL-2 production in T cells.
• Controls: CD155-deficient mice or isotype controls are commonly used for comparison.

In summary, clone 4.24.1 is used in vivo to probe the role of CD155 in mouse models, especially in immune regulation and cancer, by neutralizing CD155 and assessing subsequent biological effects.

I don't have specific information available about what 4.24.1 refers to or what antibodies or proteins are commonly used with it in the literature. The search results provided discuss antibody research and applications in general, including the humanization of antibody 4A11 and various antibody techniques, but they don't contain any references to "4.24.1" or associated proteins and antibodies used with this particular designation.

To get accurate information about 4.24.1 and its commonly used associated antibodies or proteins, you would need to provide more context about what 4.24.1 represents (such as whether it's a specific antibody clone, protein designation, experimental protocol, or other biological entity) or search for literature specifically mentioning this identifier.

Based on the available search results, there is no direct information regarding any scientific findings from "clone 4.24.1" or citations associated with this specific identifier in the scientific literature.

To determine the key findings from clone 4.24.1, you would need to:

• Search peer-reviewed databases (e.g., PubMed, Web of Science, Google Scholar) using the exact identifier "clone 4.24.1" to locate relevant articles.
• Review the methodology and results sections of those articles to extract the key experimental or observational findings specific to that clone.
• Critically analyze the evidence, considering the authors' credentials, study limitations, and whether the findings are replicated or contradicted by other studies.
• Synthesize the information to present a coherent summary, highlighting any trends, gaps, or controversies in the research.

If "clone 4.24.1" refers to a specific cell line, microorganism, or genetically modified organism, the findings would only be meaningful in the context of the research question and experimental system described in the original papers.

As the provided search results do not reference the specifics of clone 4.24.1, we recommend revising your search to include the full scientific name or context (e.g., organism, experimental system) for accurate, targeted results. Without direct citations, it is not possible to summarize the key findings for clone 4.24.1 from current literature.

Dosing regimens of clone 4.24.1 (please note: the search results provided do not directly mention clone 4.24.1, but refer extensively to dosing of common checkpoint and immune-depleting antibodies in mouse models, which can inform expected regimens for similar research antibodies) can vary significantly across different mouse models, mainly depending on the target, mouse strain, and experimental goal.

• Standard dosing for similar research antibodies (such as anti-CTLA-4, anti-CD4, anti-CD8) ranges from 100–250 μg per mouse per dose, typically administered by intraperitoneal injection.
• A common schedule is every 2–3 days or 2–3 times per week to maintain antibody levels and desired biological depletion or blockade.
• For tumor immunotherapy experiments, dosing is often timed to specific days post-tumor inoculation and may be more limited due to toxicity concerns; for example, a maximum of 200 μg per antibody at days 6, 9, and 12 after tumor inoculation, with higher frequency or extended dosing potentially fatal in some models.
• Deviations in regimen can occur based on:
  • The mouse strain (immunodeficient vs. immunocompetent),
  • The disease model (tumor, infection, transplantation, etc.),
  • Experimental endpoint (e.g., acute depletion vs. chronic blockade).
• For immune cell–depleting antibodies, sustained depletion often requires repeated doses at 200–250 μg every 2–3 days.

• Researchers should always consider that mouse model-specific factors (strain differences, tumor engraftment, immune status) may necessitate adjustment of dosing or frequency to balance efficacy and minimize toxicity.

• When adapting these regimens to an unlisted or less commonly used clone such as 4.24.1, follow these general principles: start with published regimens for comparable monoclonal antibodies, monitor in vivo response and toxicity, and adjust as needed for your specific experimental model.

No search result provided direct dosing information specifically for clone 4.24.1. All regimens cited above use standards for structurally and functionally analogous antibodies in mouse translational research and may require further validation for clone 4.24.1 in your particular setting.